Natera (NTRA) Director Jonathan Sheena Sells $1.3M of Stock
Key Points
- Natera, Inc. director Jonathan Sheena sold 3,150 shares on October 21, 2026, at an average price of $410.55 per share for a total value of $1,293,245.73.
- After the trade, Jonathan Sheena holds 218,164 $NTRA shares, down 1.42% from before the trade.
- Institutional activity shows Robeco Institutional Asset Management cut its stake by 185,307 shares to 223,309 shares worth about $92,295,842, while Duquesne Family Office Llc grew its position by 122,845 shares to 3,186,306 shares valued at $1,287,108,347.
- The diagnostics company trades near its 52-week high with a market capitalization of roughly $57.86 billion and upcoming earnings scheduled for November 5, 2026.
Since the trade, $NTRA is down 1.9% to date (from the $413.38 close on Oct 21, 2026).
Get Natera text alerts
We text you when insiders, Congress, analysts or big funds move on $NTRA.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Natera, Inc. alert may contain errors. Disclosures
Natera, Inc. director Jonathan Sheena sold 3,150 shares of company stock on October 21, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The shares were disposed of at an average price of $410.55 per share, totaling roughly $1,293,245.73.
NTRA
Natera, Inc.
Inside Jonathan Sheena's NTRA Trade
The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan. Following the sale, Sheena directly owned 218,164 shares of the diagnostics company, marking a 1.42% reduction in his holdings. This follows an earlier transaction on October 16, 2026, when Sheena sold 1,500 shares. The stock closed at $413.38 on the day of the trade.
Other Institutional Activity in Natera, Inc.
Large funds continue to adjust their positions in the health care firm. Robeco Institutional Asset Management B.V. reduced its holdings by 185,307 shares, ending with 223,309 shares worth about $92,295,842. At the same time, Duquesne Family Office Llc grew its position by 122,845 shares to 3,186,306 shares valued at $1,287,108,347.
Natera, Inc. Stock Down 2.9%
Natera recently traded around $401.37 as of October 24, 2026, sitting below its 52-week high of $437.41 and well above its 200-day moving average of $260.88.
Recent Earnings
The company reported trailing-twelve-month revenue of $2,707,076,096 alongside basic earnings per share of -$1.35. The next quarterly earnings report is scheduled for November 5, 2026.
Insider Buying and Selling at Natera, Inc.
Earlier insider moves include Executive Chairman Matthew Rabinowitz selling 50,000 shares on October 15, 2026, under a planned schedule. Other insiders, including Rowan Chapman and Lynch Thomas JR., bought shares in late June 2026.
Analysts Set New Price Targets
Wall Street firms remain active on the stock. Canaccord Genuity maintained a Buy rating on October 19, 2026, while raising its price target to $500. Other firms including Barclays, Morgan Stanley, TD Cowen, and JP Morgan updated their views earlier in October.
About Natera, Inc.
Natera, Inc. is an Austin, Texas-based diagnostics and research company that develops molecular testing services. Its portfolio includes Signatera for personalized cancer recurrence monitoring and Empower for hereditary cancer screening.
Bottom Line
Investors will watch upcoming earnings on November 5, 2026, for further details on revenue growth and profitability metrics. Pre-arranged insider sales under Rule 10b5-1 plans offer a scheduled way for executives to manage personal portfolios without signaling sudden shifts in business outlook.
Related Filing Alerts
Source: Jonathan Sheena's Form 4 filing on $NTRA (Oct 21, 2026). Written by software, not financial advice. How we make alerts